Beijing Beilu Pharmaceutical Co.,Ltd’s first quarter 2026 results are off to a good start, with net profit increasing by more than 200% year-on-year.

Recently, Beijing Beilu Pharmaceutical Co., Ltd (300016) released the "2026 First Quarter Report". In 2025, the company's revenue exceeded 1.2 billion yuan for the first time, and the net profit attributable to the parent company reached 92.7347 million yuan, a year-on-year increase of 579.29%. In 2026, the company continued its strong growth momentum and once again achieved a good start in quarterly performance.

In the first quarter of 2026, Beijing Beilu Pharmaceutical Co., Ltd. achieved operating income of 320.3697 million yuan, a year-on-year increase of 13.33%; net profit attributable to shareholders of listed companies was 44.9758 million yuan, a year-on-year increase of 209.36%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 39.7177 million yuan, a year-on-year increase of 203.47%. The company's main business has shown continued and steady growth momentum, and the profitability of its core business has steadily improved, demonstrating the synergy results of its multi-dimensional strategic layout.

During the reporting period, the company's operations were stable, and the main reasons for the substantial year-on-year increase in net profit attributable to shareholders of listed companies are as follows: First, the company's various product lines have maintained a steady growth trend in this period, driving revenue and profit growth; second, the company's convertible corporate bonds will be delisted in 2025, and financial expenses in this period have been significantly reduced.

During the reporting period, after the company's chemical pharmaceutical products were gradually included in the centralized procurement and the bids were fully implemented, sales increased steadily and the profit foundation was consolidated; Tianyuan Pharmaceutical's Golden Lotus Granules, Ganmao Qingre Granules and other traditional Chinese medicine varieties have won bids for centralized procurement in many places; at the same time, the results of overseas market expansion have been evident, and the construction of an international sales network has promoted export business growth for multiple consecutive quarters. In the future, the company will continue to implement the two-wheel drive strategy of "chemical drugs + traditional Chinese medicine", and its main business will still focus on the production and sales of contrast agents, hypoglycemic drugs, chemical drugs such as central nervous system, heat-clearing and detoxifying drugs, and Chinese patent medicines. At the same time, the company will continue to promote the construction of the Lu Zhibao production base and lay a solid foundation for the long-term development of the company's Chinese patent medicine and chemical medicine sectors.